All In Biotech

Drug Trial Radar · NCT06491550

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants

A Phase I Randomized, Single-blind, Placebo-controlled, and Sequential Group Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 Following Single and Multiple Ascending Doses Via Intravenous Administration, and an Open-label, 2-Period, 2-Sequence, Cross-over Study to Assess the Effects of Intravenous AZD4144 on Rosuvastatin and Furosemide Pharmacokinetics in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Jul 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

91

Actual

Start

Jul 15, 2024

Primary completion

Jun 11, 2025

Study completion Jun 11, 2025

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jul 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study consists of 3 parts: Part A, Part B and Part C. This study will compare the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD4144 with placebo in healthy participants, in Part A and Part B. Part C of this study will investigate the possibility of drug-drug interaction (DDI) between IV AZD4144 and oral rosuvastatin and furosemide by evaluating the PK of rosuvastatin and furosemide when administered alone and in combination with single IV dose of AZD4144

Conditions

  • Healthy Participants

Interventions

  • AZD4144- Part ADrug

    Part A: Participants will be administered a single dose of AZD4144 on Day 1 via Intravenous (IV) infusion.

  • Placebo- Part ADrug

    Part A: Participants will be administered a single dose of placebo on Day 1 via IV infusion.

  • AZD4144- Part BDrug

    Part B: Participants will be administered a single dose of AZD4144 on Day 1 and Day 12 via IV infusion. Participants will be administered multiple doses of AZD4144 from Day 4 to Day 11 via IV infusion.

  • Placebo- Part BDrug

    Part B: Participants will be administered a single dose of placebo on Day 1 and Day 12via IV infusion. Participants will be administered multiple doses of placebo from Day 4 to Day 11 via IV infusion.

  • Rosuvastatin and Furosemide- Part CDrug

    Participants will be administered a single oral dose of 10 mg Rosuvastatin and 1 mg Furosemide.

  • Rosuvastatin, Furosemide, and AZD4144 Part CDrug

    Participants will be administered a single oral dose of 10 mg Rosuvastatin, 1 mg Furosemide and a single dose of AZD4144 via IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events (AEs) (Part A and Part B)Time frame: Part A: Day 1 to Day 10+3; Part B: Day 1 to Day 20+3.
  2. Area under plasma concentration-time curve from time 0 to infinity (AUCinf) (Part C)Time frame: Treatment period 1: Day 1 to 3; Treatment period 2: Day 10 to 12.
  3. Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast) (Part C)Time frame: Treatment period 1: Day 1 to 3; Treatment period 2: Day 10 to 12.
  4. Maximum observed drug concentration (Cmax) (Part C)Time frame: Treatment period 1: Day 1 to 3; Treatment period 2: Day 10 to 12.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Glendale, California

  • Research Site

    Brooklyn, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.